Liraglutide: The First-Generation GLP-1 for Diabetes & Weight Loss

Liraglutide is a first-generation GLP-1 receptor agonist with 97% homology to native human GLP-1. It binds to and activates GLP-1 receptors, stimulating glucose-dependent insulin secretion, suppressing glucagon, and slowing gastric emptying. Liraglutide has a half-life of approximately 13 hours, requiring once-daily injection. While effective for both glycemic control and weight management, it produces less weight loss than the newer once-weekly semaglutide.

Liraglutide was the second GLP-1 receptor agonist to reach the market and the first to be approved for both diabetes and weight management. Developed by Novo Nordisk, it is marketed as Victoza for type 2 diabetes (approved 2010) and Saxenda for weight management (approved 2014). Unlike newer GLP-1 medications such as semaglutide, liraglutide requires once-daily injection due to its shorter half-life of approximately 13 hours. While it has been largely superseded by semaglutide and tirzepatide for weight management, it remains a viable option and is the only GLP-1 with long-term cardiovascular outcome data from the LEADER trial spanning nearly 4 years.

The SCALE clinical trial program evaluated liraglutide 3.0 mg (Saxenda) for weight management across multiple populations. The flagship SCALE Obesity and Prediabetes trial demonstrated 8.0% mean weight loss over 56 weeks, with nearly two-thirds of participants losing at least 5% of body weight. While effective, this is notably less than the 14.9% achieved with semaglutide 2.4 mg (Wegovy) or the 22.5% achieved with tirzepatide 15 mg (Zepbound). As a result, liraglutide is now generally considered a second-line option for weight management, used when patients cannot tolerate or access the newer weekly injectables.

Liraglutide is injected once daily, in contrast to the once-weekly dosing of semaglutide and tirzepatide. Daily dosing has both drawbacks and potential advantages. The main disadvantage is inconvenience and lower adherence rates compared to weekly injections. However, daily dosing allows for more precise dose adjustments. If a patient experiences side effects, the dose can be reduced by a small increment the next day, rather than having to wait a week. Some patients also prefer the routine of a daily injection. The injection itself is subcutaneous and can be administered at any time of day, with or without food.

Semaglutide has largely replaced liraglutide as the preferred GLP-1 for both diabetes and weight management. In head-to-head trials (SUSTAIN 10), semaglutide 1 mg produced greater HbA1c reduction (-1.7% vs -1.0%) and weight loss (-5.8 kg vs -1.9 kg) compared to liraglutide 1.2 mg over 30 weeks. For weight management, semaglutide 2.4 mg produces roughly double the weight loss of liraglutide 3.0 mg. Semaglutide also offers the convenience of once-weekly dosing. However, liraglutide may still be preferred for patients who have responded well to it historically, have insurance coverage specifically for Saxenda, or prefer the flexibility of daily dosing.

Saxenda (liraglutide 3.0 mg) has a list price of approximately $1,300-$1,500 per month, making it one of the more expensive weight-loss medications despite producing less weight loss than newer options. Insurance coverage for Saxenda has declined as plans shift formulary preference toward Wegovy and Zepbound. Victoza (for diabetes) has somewhat broader coverage. Novo Nordisk offers a savings card for Saxenda that can reduce copays for commercially insured patients. As generic competition approaches (liraglutide patents have begun to expire), biosimilar versions may offer lower-cost alternatives in the near future.